Recent Analysts’ Ratings Updates for Tarsus Pharmaceuticals (TARS)

Several brokerages have updated their recommendations and price targets on shares of Tarsus Pharmaceuticals (NASDAQ: TARS) in the last few weeks:

• 9/24/2026 – Tarsus Pharmaceuticals is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $116.00 price target on the stock.
• 9/24/2026 – Tarsus Pharmaceuticals had its “buy” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $116.00 price target on the stock.
• 9/16/2026 – Tarsus Pharmaceuticals is now covered by Barclays PLC. They set an “overweight” rating and a $110.00 price target on the stock.
• 9/16/2026 – Tarsus Pharmaceuticals had its “overweight” rating reaffirmed by Barclays PLC. They now have a $110.00 price target on the stock.
• 9/8/2026 – Tarsus Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $88.00 to $105.00. They now have a “buy” rating on the stock.
• 9/4/2026 – Tarsus Pharmaceuticals had its price target raised by Jefferies Financial Group Inc. from $88.00 to $105.00. They now have a “buy” rating on the stock.
• 8/12/2026 – Tarsus Pharmaceuticals had its price target raised by Oppenheimer Holdings, Inc. from $97.00 to $100.00. They now have an “outperform” rating on the stock.

Insider Buying and Selling at Tarsus Pharmaceuticals

In other news, Director William Link, PhD sold 12,500 shares of Tarsus Pharmaceuticals stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $78.38, for a total transaction of $979,750.00. Following the completion of the transaction, the director directly owned 94,487 shares in the company, valued at approximately $7,405,891.06. This trade represents a 11.68% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Bobak Azamian sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, September 4th. The stock was sold at an average price of $90.56, for a total value of $905,600.00. Following the completion of the sale, the chief executive officer directly owned 827,991 shares in the company, valued at approximately $74,982,864.96. This represents a 1.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 48,031 shares of company stock valued at $4,004,227. Corporate insiders own 9.64% of the company’s stock.

Tarsus Pharmaceuticals, Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for diseases and conditions affecting the eye. The company concentrates on areas of significant unmet need in ophthalmology and aims to address conditions that can affect ocular health, comfort and vision.

Tarsus’ primary product is XDEMVY (lotilaner ophthalmic solution) 0.25%, an eye drop approved by the U.S. Food and Drug Administration in 2023 for the treatment of Demodex blepharitis.